New pill for arthritis pain enters early human safety trial
NCT ID NCT06628206
First seen Nov 20, 2025 · Last updated May 13, 2026 · Updated 22 times
Summary
This early-stage study tests an experimental oral drug called LPX-TI641 in 48 adults with rheumatoid arthritis or psoriatic arthritis. Participants will receive either the drug or a placebo daily for 28 days. The main goal is to check if the drug is safe and tolerable, and how it behaves in the body. This is not a cure; it aims to help manage the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Triumpharma Clinical Research Unit at AlEssra Hospital
RECRUITINGAmman, ST B204, Jordan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.